Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Ovarian 200: Avelumab +/- PLD in Platinum-Resistant/Refractory Ovarian Cancer
NCT02580058Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2015
- Primary completion
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 25
01
Overview
A Phase 3 trial of avelumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Pfizer. Started Dec 2015; status: completed.
02
Drugs
avelumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02580058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02580058.